News

Tue, 2012-11-13

ViroPharma's Cinryze(R) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With HAE

EXTON, Pa., Nov. 13, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced important data from an open-label, multicenter study to assess the safety, tolerability, and treatment effect of escalating doses of C1 INH-nf in patients with HAE who were not adequately controlled with 1000 U every 3 or 4 days.

The results of this study were presented at the 2012 annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Anaheim, California.

The data provide evidence for the safety profile of Cinryze® (C1 esterase inhibitor [human]) at doses up to 2500 units in patients with hereditary angioedema (HAE). HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of a human plasma protein called C1 inhibitor.

The presentation titled, Safety and Efficacy of Escalating Doses of C1 Esterase Inhibitor [Human] (Cinryze) as Prophylaxis in Patients with Hereditary Angioedema (HAE) was presented by Dr. Jonathan A. Bernstein from the University of Cincinnati. The study was a post marketing FDA requirement to assess the safety and tolerability of escalating doses of Cinryze, with specific interest in thrombogenicity and immunogenicity.

This study enrolled 20 eligible subjects over a 3 year period. Subjects with qualifying HAE attack rates, and who met other specified entry criteria, were entered into a 3-step dose-escalation algorithm. Each step consisted of 12 weeks of sequential Cinryze dose escalation of 1500, 2000, and 2500 units with infusions every 3 or 4 days if the subject continued to have an average of > 1.0 angioedema attacks/month, regardless of severity. An additional 3 month safety follow-up occurred with successful completion of a dose escalation step. The authors concluded that doses up to 2500 units every 3 or 4 days may be considered for patients who do not respond to 1000 units twice weekly.

The results of the study showed that:

 

  • Overall, the safety profile of Cinryze doses up to 2500 units was consistent with previous clinical trial experience at lower doses; 
  • No systemic thrombotic events occurred during this study; 
  • At all dosage levels, Cinryze was well tolerated, with no discontinuations due to an adverse event (AE); 
  • The majority of AEs were mild to moderate intensity;
  • During the 12 month study, 2 patients experienced AEs that the investigator considered to be related to study medication (1 with localized blood clot in a port-a-cath on Day 81 treated with streptokinase, catheter-site pain on first day of dosing of two dose escalation steps, and dyspnea on Day 173 and 1 with muscle spasm); 
  • Two patients experienced serious adverse events unrelated to study medication (one with cerebral cystic lymphangioma and one with worsening anemia and bile duct stone); 
  • In one patient, C1 INH antibodies were detected at baseline (pre-dose Day 1) and in all samples collected during the study while receiving doses up to 2500 units. Another patient developed borderline detectable antibodies to C1 inhibitor while receiving 2500 units of study drug. 

"The study analysis of these data provides insight into the safety and efficacy of dose escalation of Cinryze up to 2500 units," commented Dr. Jonathan A. Bernstein, professor of clinical medicine, Department of Internal Medicine, University of Cincinnati Medical Center, "Previous Cinryze studies show that patients had reductions in the frequency, severity, and duration of angioedema attacks while receiving 1000 units; however, some patients were not adequately controlled at this dose. We are pleased to see that higher doses of Cinryze do not result in systemic thrombotic events, and may be considered for patients with HAE who do not respond to lower doses."

 

Teaser 4, 2nd row left, in news section

United We Stand Strong!

HAEi cares about you. We encourage patients to get organized - because "United We Stand Strong".

HAE International - Thumb 7HAE International - Thumb 7Become a National Member Organization (NMO). We are here to help you in founding a National Member Organization. Follow our step-by-step model. It doesn't have to be a difficult task creating the best foundation for patients in your country. Contact us for more information here


HAE International - Thumb 4HAE International - Thumb 4

Starting a National Patient Group (NPG). If you are interested in doing more around HAE - but don't feel that starting a full NMO is the right option here and now. You should maybe consider becoming a contact patient (NPG) for your country. Contact us here

Both NMO's and NPG's enjoy free membership of HAEi. Also we can help you host your country specific website under the global umbrella of HAEi.

Events

Thu, 2015-05-28 13:00 - Sun, 2015-05-31 14:00

9th C1 Inhibitor Deficiency Workshop

Venue: Danubius Thermal Hotel Margitsziget, Margitsziget, 1133 Budapest, Hungary
Language: English

It is our great pleasure to invite you to the 9th C1-INH Deficiency Workshop. This event has a history of many years, as well as its nature and objectives are familiar to many of us. Nevertheless, given the continued interest from first-time attendees, we would like to introduce the Workshop for them in brief, as follows.

This conference focuses on bradykinin-mediated angioedemas, and particularly on the types resulting from C1-inhibitor deficiency. The topics of this four-day long event cover a wide range of subjects.

Read more about the workshop here.

..continue
Fri, 2015-02-20 10:00 - Tue, 2015-02-24 16:00

AAAAI - Annual Meeting 2015

Venue: Houston, TX, United States of America
Language: English

Mark your calendars and head to Houston, Texas for the premier event in allergy/immunology. You will be able to earn CME/CE, learn about cutting-edge research and enrich your networking connections at the 2015 AAAAI Annual Meeting, February 20-24.

For more information please visit: AAAAI 2015
..continue
Sat, 2014-12-06 09:00 - Tue, 2014-12-09 15:00

WAO International Scientific Conference 2014

Venue: SulAmérica Convention Center, Av Paulo de Frontin, 1 - New City, Centro Rio de Janeiro - RJ, Brazil
Language: English

Advancing the borders of allergy: From treatment to prevention by targeting the environment, infections and the susceptible patient

We are delighted to welcome you to participate in the WAO International Scientific Conference 2014 (WISC 2014) and the XLI Annual Congress of the Brazilian Association of Allergy and Immunology (ASBAI) in Rio de Janeiro, Brazil, 6-9 December 2014.

..continue

Homepage Teaser 6, 2nd row right

HAE Global Community

Be part of the HAEi Community

HAEi is here to help you. Therefore we have created the HAEi Community that gives you all the bells and whistles you know from other social media (such as Facebook) and even a very sophisticated Forum, where you can discuss with fellow HAE patients and care givers. The only difference is - that here your information stays safe - and will only be shared with other HAE patients and care givers. If you are a HAE patient or directly related to a HAE patient we urge you to register today - and become an important member of our community

Help yourself and stay updated by registering already today - then you will be the first to know.....

Do you have Questions?
You can find answers on our FAQ-Page or
send us an e-mail to: info@haei.org
or go to the contact form page


Experiencing browser problems?

Our website is working properly on most web browsers. However, we know that the site will not perform correctly on Microsoft Internet Explorer version 6 and earlier! So if you are using Internet Explorer from Microsoft please ensure that you have version 7 or higher!


See the video from the 2012 HAE Global Conference in Copenhagen

Click here


HAEDAYHAEDAYLook out for next hae day :-) on 16 May 2014


www.haeday.org